Samjin Pharmaceuticals Co., Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.
June 16, 2023 at 12:18 am EDT
Share
Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a trust contract with Mirae Asset Securities Co., Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on December 15, 2023.
As of June 15, 2023, the company had 897,920 shares in treasury within scope available for dividend and had 0 shares in treasury through other repurchase.
Samjin Pharmaceuticals co., LTD. is a Korea-based company mainly engaged in the manufacture of pharmaceutical products. The Companyâs products include antipyretics, analgesics, antiphlogistic agents, osteoarthritis agents, osteopathic agents, antihistaminic agents, circulatory system drugs, gastrointestinal agents, osteoporosis treatments, hepatic disease agents, respiratory agents, antibiotics agents, detoxifying agents, antifungal agents, antineoplastic agents and others. Its products are provided in the forms of tablets, injections, capsules and others. It distributes its products to the hospitals and drugstores. The Company supplies its products within domestic market and to overseas markets.
SAMJIN PHARMACEUTICALS CO., LTD. 
